Section 5: Patient Safety and Quality Assurance

5PSQ-128

COST-EFFECTIVENESS OF PHARMACEUTICAL PREOPERATIVE CONSULTATIONS: A FIVE-YEAR ANALYSIS

5PSQ-127

MEDICATION-RELATED FALLS IN A NURSING HOME: IDENTIFICATION AND HOSPITAL PHARMACY INTERVENTIONS

5PSQ-126

THE ANALYSIS OF INTERACTIONS AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN HOSPITALIZED SENIORS

5PSQ-125

ANALYSIS OF INTRODUCING PROBIOTICS FOR THE PREVENTION OF NECROTIZING ENTEROCOLITIS IN PREMATURE NEONATES IN A NEONATAL UNIT

5PSQ-124

THE TREATMENT OF PRESSURE ULCERS WITH BACTERIA BINDING MEDICATION AS A VALID THERAPEUTIC OPPORTUNITY

5PSQ-123

SIMUALTION OF A DISCHARGE CONTROL: AN EFFECTIVE TOOL FOR QUALIFYING STAFF

5PSQ-122

SEQUENTIAL CHANGE OF DOSING INTERVAL OF PALIPERIDONE PALMITATE BASED ON PLASMA CONCENTRATION MONITORING

5PSQ-121

A REVIEW OF THE EXPOSURE TO POTENTIALLY HARMFUL EXCIPIENTS THROUGH ORAL LIQUID FORMS IN PEDIATRIC INPATIENTS IN FRANCE

5PSQ-120

PEMBROLIZUMAB IMMUNE-MEDIATED TOXICITY

5PSQ-119

REVIEW OF REAL-WORLD MANAGEMENT OF NATALIZUMAB TREATMENT IN MULTIPLE SCLEROSIS: A DOUBLE-EDGED WEAPON

5PSQ-118

NON-ACTIVE PRESCRIPTIONS IN AMBULATORY PATIENTS: ANALYSIS AND EFFECT IN CONSULTATION WAITING TIME

5PSQ-117

TRACEABILITY OF IMPLANTABLE MEDICAL DEVICES / PATIENT INFORMATION: WHERE DO WE STAND?

5PSQ-116

REAL-WORLD PERSISTENCE WITH GUSELKUMAB AMONG ADULTS WITH PSORIATIC ARTHRITIS

5PSQ-115

EVALUATION OF HYPOTHYROIDISM ASSOCIATED WITH APALUTAMIDE AND ENZALUTAMIDE TREATMENT IN METASTATIC PROSTATE CANCER USING THE EUROPEAN ADVERSE EFFECT DATABASE (EUDRAVIGILANCE)

5PSQ-114

HEAD AND NECK ERYTHEMA ASSOCIATED WITH THE USE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS

Pages